Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label Expanded Access Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to or Failing Standard Chemotherapy

Next Previous
Search
Trial Profile

An Open-Label Expanded Access Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to or Failing Standard Chemotherapy

Status: Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 09 Sep 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tipiracil/trifluridine (Primary)
  • Indications Adenocarcinoma; Colorectal cancer
  • Focus Adverse reactions; Expanded access
  • Sponsors Taiho Pharmaceutical

    • Most Recent Events

    • 20 Jan 2018 Results assessing the safety and tolerability profile of trifluridine/tipiracil (FTD/TPI) in elderly patients with metastatic colorectal cancer, presented at the 2018 Gastrointestinal Cancers Symposium.
    • 06 Jun 2017 Results (n=45) assessing the safety of trifluridine/tipiracil for metastatic colorectal cancer in African American patients, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 02 Jun 2017 Results assessing safety presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top